NewGenIvf Group Limited (NIVF) Key Metrics
NIVF valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.9M
- Enterprise value
- $5.6M
- P/E (TTM)
- —
- Forward P/E
- 0.0
- PEG ratio
- —
- Price / sales
- 0.4
- Price / book
- 0.1
- EV / EBITDA
- 0.5
- Dividend yield
- —
- Beta
- 0.06
NIVF key metrics, 2021–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNIVF returns How much profit the business earns on the capital it uses.
NIVF financial health Debt, liquidity and how easily interest is covered.
NIVF efficiency & capital use Working capital cycle and where the cash goes.
NIVF returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NIVF debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NIVF price vs earnings per share
NIVF key metrics
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | — | — | $5.43T | — | — |
| Enterprise value | — | — | $5.43T | — | — |
| Earnings yield | — | — | −0.0% | — | — |
| Free cash flow yield | — | — | −0.0% | — | — |
| Dividend yield | — | — | 0.0% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | 0.0% | — | — |
| Share price at fiscal year-end | $298.08 | $874,800.00 | $1,000,004.40 | $1,000,004.40 | — |
| Per share | |||||
| Revenue per share | — | — | $0.95 | — | — |
| Earnings per share | — | — | −$0.13 | — | — |
| Operating cash flow per share | — | — | −$0.16 | — | — |
| Free cash flow per share | — | — | −$0.17 | — | — |
| Cash per share | — | — | $0.01 | — | — |
| Book value per share | — | — | $2.87 | — | — |
| Tangible book value per share | — | — | $2.87 | — | — |
| Dividends per share | — | — | $0.00 | — | — |
| Capex per share | — | — | $0.01 | — | — |
| Debt per share | — | — | $0.30 | — | — |
| Shares outstanding | — | — | 5.4M | — | — |
| Returns & profitability | |||||
| Return on equity (ROE) | 77.2% | — | −8.6% | — | — |
| Return on invested capital (ROIC) | −52.5% | −9.8% | −21.9% | 36.0% | 82.0% |
| Return on assets (ROA) | 54.4% | −4.2% | −5.7% | 21.2% | −0.0% |
| Return on tangible assets | 102.1% | −14.7% | −3.2% | 15.8% | −0.0% |
| Free cash flow margin | −352.8% | −153.1% | −18.1% | −10.5% | 34.4% |
| Income quality (OCF / net income) | −1.11 | — | — | −1.15 | — |
| Financial health | |||||
| Total debt | $4.9M | $3.0M | $1.6M | $452,042 | $925,968 |
| Cash & short-term investments | $758,621 | $457,740 | $42,224 | $27,556 | $28,764 |
| Net debt | $4.1M | $2.6M | $1.6M | $424,486 | $897,204 |
| Debt / equity | 0.18 | — | 0.10 | 0.80 | — |
| Debt / assets | 0.15 | 0.85 | 0.08 | 0.16 | 0.66 |
| Net debt / EBITDA | 0.38 | 106.02 | — | 0.58 | 1.53 |
| Current ratio | 3.12 | 1.17 | 0.02 | 0.94 | 0.40 |
| Quick ratio | 2.98 | 1.14 | −0.03 | 0.92 | 0.38 |
| Interest coverage | -17.4 | -1.5 | -54.6 | 5.1 | 2.3 |
| Working capital | $5.0M | $452,391 | −$2.2M | −$157,027 | −$1.2M |
| Invested capital | $30.7M | $1.5M | $17.2M | $987,599 | $121,266 |
| Tangible asset value | $2.9M | −$1.5M | $15.6M | $100,683 | −$914,910 |
| Net current asset value | $647,495 | −$1.9M | −$5.7M | −$405,660 | −$1.5M |
| Graham net-net per share | — | — | −$0.89 | — | — |
| Capital allocation | |||||
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Dividend payout ratio | 0.0% | — | — | 0.0% | — |
| Dividends + buybacks / free cash flow | — | — | — | — | 0.0% |
| Capex / revenue | 121.7% | 1.0% | 1.4% | 1.6% | 0.4% |
| Capex / operating cash flow | — | — | — | — | 1.2% |
| Capex / depreciation | 11.51 | 0.26 | 0.30 | 0.31 | 0.05 |
| SG&A / revenue | 247.2% | 55.0% | 31.9% | 19.2% | 20.1% |
| Efficiency | |||||
| Days sales outstanding | 132.5 | 113.7 | 118.9 | 94.4 | 66.5 |
| Days of inventory on hand | 20.1 | 10.5 | 9.1 | 3.7 | 4.9 |
| Days payables outstanding | 100.6 | 74.5 | 14.6 | 6.3 | 5.5 |
| Cash conversion cycle (days) | 52.1 | 49.7 | 113.4 | 91.8 | 65.8 |
| Receivables turnover | 2.75 | 3.21 | 3.07 | 3.87 | 5.49 |
| Payables turnover | 3.63 | 4.90 | 24.92 | 58.14 | 65.91 |
| Inventory turnover | 18.12 | 34.83 | 39.89 | 99.94 | 74.94 |
| Asset turnover | 0.26 | 0.44 | 0.42 | 2.75 | 2.91 |
| Average receivables | $1.7M | $1.7M | $1.7M | $1.5M | $750,351 |
| Average payables | $1.0M | $735,795 | $138,638 | $75,789 | $46,927 |
| Average inventory | $208,086 | $103,538 | $86,587 | $44,090 | $41,271 |
| Intangibles / total assets | 70.4% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from NIVF's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NIVF valuation and financial ratios
NewGenIvf earned a return on equity of 77.2% and a return on invested capital of −52.5% in fiscal 2025. It ended the year with $4.9 million of debt and $0.8 million in cash and short-term investments, net debt of $4.1 million.
See the NIVF income statement, the NIVF chart for price history, or the NIVF stock overview for the latest quote and news.
NIVF key metrics FAQ
What is NewGenIvf's return on equity?
NewGenIvf's return on equity (ROE) was 77.2% in fiscal 2025: net income of $9.9 million on average shareholders' equity of $12.8 million.
What is NewGenIvf's ROIC?
NewGenIvf's return on invested capital was −52.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does NewGenIvf have?
NewGenIvf had total debt of $4.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.18 and $4.1 million of net debt (0.38 times EBITDA).
Does NewGenIvf pay a dividend?
NewGenIvf did not pay a dividend in fiscal 2025.
What is NewGenIvf's current ratio?
NewGenIvf's current ratio was 3.12 at the end of fiscal 2025: current assets were 3.12 times current liabilities.